Nektar Therapeutics

Fundamentals6.0
Price Action3.0
News Sentiment4.0
AI Rating
4.0

Key Drivers

  • Liquidity Strength
  • Persistent Losses
  • Rich Valuation

AI
AI Summary

4.0

NKTR is no longer a balance-sheet survival story—its bigger cash cushion buys time, but investors are now betting on binary pipeline milestones to justify a still-rich valuation amid a serious legal overhang.

CashRunway
Legal
Pipeline‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Liquidity Strength
  • Persistent Losses
  • Rich Valuation

NKTR's Q1 2026 results show a much stronger liquidity position, but the company remains loss-making with negative cash flow and a valuation that looks rich relative to fundamentals.

Liquidity
Overvalued

Price Behavior

3.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Support test
  • Overhead resistance

Over the last month, NKTR's sharp spike to $100.35 quickly reversed into a clear downtrend, with $70-$71 now acting as key near-term support and the mid-$70s to low-$80s area as overhead resistance.

bearish
neutral
Support Level: $70-$71
Resistance Level: mid-$70s to low $80s

Sharp spike to $100.35 on 2026-04-20 before a steep reversal

Sentiment & News

4.0

Key News Insights:

  • Capital Raise
  • Legal Overhang
  • Cash Strength

Nektar boosted liquidity with a $250M offering and Q1 cash rising to $731.6M, but the stock remains weighed by an active securities class action and escalating disclosure-related litigation.

litigation
liquidity

The stronger balance sheet improves near-term flexibility, but ongoing litigation is likely to keep pressure on sentiment and valuation